NeoMET Study in Neoadjuvant Treatment of Breast Cancer
Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
To evaluate docetaxel, epirubicin and cyclophosphomide (TEC) with TEC plus metformin in
neoadjuvant treatment of breast cancer patients. The aim is to evaluate whether metformin can
increase the pCR rate combination with TEC regimen in neoadjuvant setting.